Skip to main content

MARSHALL WACE, LLP

Position in ESPR — Esperion Therapeutics, Inc.

CIK 1318757 LONDON, X0

Position in ESPR

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$0
+$0 QoQ
Shares Held
14,118
-99.8% QoQ
Ownership
0.005%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
not a current holder
Holding Since
Mar 2020
23 quarters on record
Voting authority Sole 0% Shared 100% None 0%

Common Shares in ESPR Over Time

Shares Held

Position Value (USD)

Derivatives in ESPR

reported options exposure · as of Jun 30, 2020
CallValue
$0
CallShares
300,000
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Drug Manufacturers - Specialty & Generic

Healthcare · as of Jun 30, 2026

MARSHALL WACE, LLP holds $609,159,561 across 30 Drug Manufacturers - Specialty & Generic names. ESPR ranks #30 (0.0% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in ESPR

Export CSV
24 filing rows on record
Report Date Value (USD) Shares
2026-06-30 14,118
2026-03-31 7,075,083
2025-12-31 5,471,611
2025-09-30 2,521,439
2025-06-30 5,312,252
2025-03-31 3,632,958
2024-09-30 3,092,629
2024-06-30 4,303,596
2024-03-31 2,215,961
2023-12-31 457,758
2023-09-30 1,574,136
2023-06-30 315,929
2023-03-31 287,605
2022-12-31 175,023
2022-09-30 560,987
2022-06-30 26,600
2021-09-30 520,095
2021-06-30 1,172,070
2021-03-31 1,029,701
2020-12-31 1,375,930
2020-09-30 1,366,105
2020-06-30 1,290,774
2020-06-30 300,000
2020-03-31 1,323,947